Literature DB >> 18259753

Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy.

Hidenari Nagai1, Daisuke Miyaki, Teppei Matsui, Masahiro Kanayama, Katsuya Higami, Kouichi Momiyama, Takashi Ikehara, Manabu Watanabe, Yasukiyo Sumino, Kazumasa Miki.   

Abstract

PURPOSE: It has been reported that Th2 cytokines down-regulate antitumor immunity, while activation of type 1 T cells promotes antitumor immunity. However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear. The aim of this study was to assess the influence of intra-arterial combination chemotherapy on the Th1/Th2 balance in LC patients with aHCC.
METHODS: Twenty-one adult Japanese LC patients with aHCC were treated by intra-arterial combination chemotherapy. The control group was composed of 20 adult Japanese patients with chronic hepatitis C diagnosed from examination of liver biopsy specimens. All control patients were over 55 years old and were stage 1 according to the fibrosis score of Desment.
RESULTS: Thirteen of the 21 aHCC patients (group R) showed an objective response, but the other 8 patients (group N) showed no response. There were no significant differences of Th1 cells between group R and group N either before or after chemotherapy. Although there was no significant difference from group R, group N had a significantly higher percentage of Th2 cells than the control group both before and after chemotherapy (p < 0.05 by Tukey's test).
CONCLUSIONS: These results indicate that the Th1/Th2 balance might be a useful indicator of the effect of intra-arterial combination chemotherapy in LC patients with aHCC. Inhibition of an increase of Th2 cells might be important for the efficacy of intra-arterial chemotherapy in such patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259753     DOI: 10.1007/s00280-008-0685-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.

Authors:  Xudong He; Yifan Cao; Yun Gu; Hanji Fang; Jieti Wang; Xin Liu; Kunpeng Lv; Kuan Yu; Yuchao Fei; Chao Lin; Hao Liu; Heng Zhang; He Li; Jiejie Xu; Ruochen Li; Hongyong He
Journal:  Ann Surg Oncol       Date:  2021-03-18       Impact factor: 5.344

2.  Effects of anesthetic methods on preserving anti-tumor T-helper polarization following hepatectomy.

Authors:  Di Zhou; Fang-Ming Gu; Qiang Gao; Quan-Lin Li; Jian Zhou; Chang-Hong Miao
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

3.  Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.

Authors:  Ja Seon Kim; Young Min Park; Nha Young Kim; Han Kyeol Yun; Ki Jong Lee; Bo Hyun Kim; Sang Jong Park; Jae Woo Yeon; Guhung Jung
Journal:  Korean J Hepatol       Date:  2011-06

4.  Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes.

Authors:  Teodora Mocan; Cornel Iancu
Journal:  Int J Nanomedicine       Date:  2011-09-12

5.  Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.

Authors:  Hidenari Nagai; Takanori Mukozu; Daigo Matsui; Takenori Kanekawa; Masahiro Kanayama; Noritaka Wakui; Kouichi Momiyama; Mie Shinohara; Kazunari Iida; Koji Ishii; Yoshinori Igarashi; Yasukiyo Sumino
Journal:  Clin Dev Immunol       Date:  2012-05-14

6.  Antitumor effect of embryonic stem cells in a non-small cell lung cancer model: antitumor factors and immune responses.

Authors:  Wei Dong; Chen Qiu; Hongchang Shen; Qi Liu; Jiajun Du
Journal:  Int J Med Sci       Date:  2013-08-09       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.